Duracillin A-S
(Penicillin)Phase 3Small molecule
SanofiThis antibiotic injection is used to treat bacterial infections by killing the bacteria that cause them. It is administered as an injection into the muscles and is not effective against viral infections like colds or flu.[1] Duracillin A-S is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Duracillin A-S is one of 8 small molecule programs targeting Staphylococcus Aureus. It is currently in Phase 3.
1
Indications
6
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Staphylococcus Aureus
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ancef
BBaxter Healthcare Corporation
Approved
Trimethoprim-Sulfamethoxazole
AstellasPhase 3
Duracillin A-S
SanofiPhase 3
Chirocaine
PPurdue Pharma LP
Preclinical
AZD7760
AstraZenecaPreclinical
Neosporin
NNorthwestern University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tonsillitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Penicillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]